Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$48.30 USD
+0.46 (0.96%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $48.29 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth B Momentum B VGM
Bristol Myers Squibb (BMY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$56.32 | $69.00 | $40.00 | 17.73% |
Price Target
Based on short-term price targets offered by 19 analysts, the average price target for Bristol Myers Squibb comes to $56.32. The forecasts range from a low of $40.00 to a high of $69.00. The average price target represents an increase of 17.73% from the last closing price of $47.84.
Analyst Price Targets (19)
Broker Rating
Bristol Myers Squibb currently has an average brokerage recommendation (ABR) of 2.68 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 24 brokerage firms. The current ABR compares to an ABR of 2.71 a month ago based on 23 recommendations.
Of the 24 recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 16.67% and 4.17% of all recommendations. A month ago, Strong Buy represented 17.39%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 5 |
Buy | 1 | 1 | 0 | 0 | 0 |
Hold | 18 | 18 | 18 | 17 | 16 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.68 | 2.68 | 2.71 | 2.70 | 2.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/9/2024 | Not Identified | Not Identified | Hold | Hold |
4/1/2024 | William Blair | Matt Phipps | Hold | Hold |
3/27/2024 | Guggenheim Securities | Seamus Fernandez | Hold | Hold |
3/11/2024 | Societe Generale | Justin S Smith | Not Available | Hold |
2/6/2024 | Daiwa America | Narumi Nakagiri | Moderate Buy | Moderate Buy |
11/15/2023 | Cantor Fitzgerald & Co | Olivia Brayer | Strong Buy | Hold |
11/1/2023 | Berenberg Bank | Luisa Hector | Hold | Hold |
10/27/2023 | BMO Capital Markets | Evan Seigerman | Strong Buy | Hold |
10/26/2023 | SVB Securities | David Risinger | Hold | Hold |
9/6/2023 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.68 |
ABR (Last week) | 2.68 |
# of Recs in ABR | 24 |
Average Target Price | $56.32 |
LT Growth Rate | 5.00% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 82 of 252 |
Current Quarter EPS Est: | -4.47 |